Ebola virus vaccines: Where do we stand?

Area of Science:

• Infectious Diseases
• Vaccinology
• Public Health

Background:

• The West Africa Ebola virus disease outbreak (2014) resulted in over 11,000 fatalities.
• The World Health Organization (WHO) identified an urgent need for expedited clinical trials of Ebola vaccine candidates.
• Vaccines are crucial for managing outbreaks and providing long-term protection against sporadic Ebola virus disease (EVD) events.

Purpose of the Study:

• To review the clinical development of two leading first-generation Ebola virus vaccine candidates.
• To discuss the opportunities and challenges associated with the licensure and deployment of these vaccines.
• To provide an overview of the current landscape of Ebola vaccine research and development.

Main Methods:

• Focus on two advanced vaccine candidates: replication-defective chimpanzee adenovirus 3 (ChAd3) and live replicating vesicular stomatitis virus (rVSV).
• Review of existing clinical trial data and scientific literature pertaining to these vaccine candidates.
• Analysis of factors influencing vaccine licensure and global deployment strategies.

Main Results:

• Both rVSV and ChAd3 vaccines have undergone Phase 1 trials, demonstrating varying safety and immunogenicity profiles.
• Ongoing research aims to establish robust efficacy data necessary for regulatory approval.
• The review highlights the critical need for continued investment in Ebola vaccine research.

Conclusions:

• The development of effective Ebola virus vaccines is a priority for global health security.
• Addressing challenges in clinical testing, licensure, and equitable deployment is essential.
• Continued collaboration and research are vital to control and prevent future Ebola outbreaks.